OneMedNet Executes on Growth Strategy: Secures Over $3 Million in New Bookings, Surpassing Full-Year 2025
OneMedNet Corp. (Nasdaq: ONMD) said it secured more than $3 million in new bookings for 2026 as of June 10, exceeding full-year 2025 bookings, and expects substantially all to convert to revenue by end of Q3 2026, according to the company. Growth is tied to demand for regulatory-grade multi-modal real-world data via its iRWD platform.
Bookings acceleration and fast conversion guidance are a near-term fundamental catalyst for ONMD’s revenue trajectory.
OneMedNet says it secured over $3M in 2026 bookings to date, surpassing full-year 2025, with revenue conversion expected by Q3 2026.
Likely positive bias for the stock as traders price in faster revenue recognition into Q3 2026.
Background
OneMedNet provides regulatory decision-grade, AI-driven real-world data (RWD) via its iRWD™ platform, including multi-modal, imaging-centric datasets.
Why it matters
The company reports a step-change in commercial momentum (bookings) and provides a concrete expected revenue conversion window (by end of Q3 2026), which can re-rate near-term growth expectations.
Market relevance
A fresh bookings milestone that exceeds full-year 2025 and is expected to convert to revenue by Q3 2026 is a direct catalyst for ONMD’s growth outlook.
Market effects
Supports the narrative that regulatory-grade real-world data and multi-modal datasets are seeing accelerating enterprise demand.
No specific regional impact beyond US-listed healthcare/AI data services.
Primarily US-focused disclosure, but the regulatory-submission use case is globally relevant for life sciences.
Alternative perspectives
Bookings growth may not translate into durable profitability; traders may discount if margins, customer concentration, or renewal rates aren’t addressed.
The release doesn’t quantify total contract value remaining in the pipeline, customer names, or gross margin impact—key for assessing whether bookings-to-revenue converts into earnings power.
Key entities
- companyOneMedNet Corporation
Nasdaq-listed provider of regulatory decision-grade, AI-driven real-world data; reports >$3M 2026 bookings YTD and expected Q3 2026 revenue conversion.
- product_platformiRWD™ Platform
OneMedNet’s platform for regulatory-grade multi-modal real-world data used for regulatory submissions and AI model development.
- technology_partnerPalantir Foundry
Platform technology powering iRWD™ per the release.
